ArticleCancer medicine2022

Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China.

Xiwen Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.